内容紹介
A Case of StageⅣ Breast Cancer Successfully Treated Over 1 Year with Eribulin as Fourth-Line Systemic Chemotherapy
Summary
A 59-year-old woman with an exudative, reddish bilateral breast tumor and dyspnea visited our hospital. She was diagnosed as having scirrhous carcinoma with metastasis to the liver and pleural effusion, designated as StageⅣ, hormone receptor positive, and human epidermal growth factor receptor-2(HER2)negative. Systemic chemotherapy(3 regimens)and endocrine therapy(5 regimens)were administered for a total of 5 years 7 months. Eribulin was administered as fourth-line systemic chemotherapy. The pleural effusion reduced and dyspnea improved. Her status was maintained for 1 year 3 months. This case suggests that eribulin may provide long-term survival and maintenance of quality of life(QOL)in metastatic breast cancer patients.
要旨
症例は59歳,女性。両側乳房の腫瘤・発赤,労作時の呼吸困難を主訴に当科を受診した。両側胸水と肝転移を伴うStageⅣ乳癌[硬癌: ER(+),PgR(+),HER2(-)]と診断された。約5年7か月の間に化学療法を3レジメン,内分泌療法を5レジメン施行した。fourth-lineの化学療法としてエリブリンの投与を開始し,両側胸水の減少と呼吸困難の改善を認めた。PDとなるまで約1年3か月外来投与を継続できた。エリブリンは,StageⅣ乳癌の治療において生存期間の延長とQOLの維持に寄与するものと思われた。
目次
Summary
A 59-year-old woman with an exudative, reddish bilateral breast tumor and dyspnea visited our hospital. She was diagnosed as having scirrhous carcinoma with metastasis to the liver and pleural effusion, designated as StageⅣ, hormone receptor positive, and human epidermal growth factor receptor-2(HER2)negative. Systemic chemotherapy(3 regimens)and endocrine therapy(5 regimens)were administered for a total of 5 years 7 months. Eribulin was administered as fourth-line systemic chemotherapy. The pleural effusion reduced and dyspnea improved. Her status was maintained for 1 year 3 months. This case suggests that eribulin may provide long-term survival and maintenance of quality of life(QOL)in metastatic breast cancer patients.
要旨
症例は59歳,女性。両側乳房の腫瘤・発赤,労作時の呼吸困難を主訴に当科を受診した。両側胸水と肝転移を伴うStageⅣ乳癌[硬癌: ER(+),PgR(+),HER2(-)]と診断された。約5年7か月の間に化学療法を3レジメン,内分泌療法を5レジメン施行した。fourth-lineの化学療法としてエリブリンの投与を開始し,両側胸水の減少と呼吸困難の改善を認めた。PDとなるまで約1年3か月外来投与を継続できた。エリブリンは,StageⅣ乳癌の治療において生存期間の延長とQOLの維持に寄与するものと思われた。